Approved indications: Padcev is approved for adults with bladder or urinary tract (urothelial) cancer: (1) in combination with pembrolizumab (with or without berahyaluronidase alfa‑pmph) as neoadjuvant therapy before, and then adjuvant therapy after, cystectomy for cisplatin‑ineligible muscle‑invasive bladder cancer; (2) in combination with pembrolizumab for locally advanced or metastatic urothelial cancer regardless of cisplatin eligibility; and (3) as a single agent for locally advanced or metastatic urothelial cancer in adults who have received both platinum‑containing chemotherapy and a PD‑1/PD‑L1 inhibitor, or who are ineligible for cisplatin and have received at least one prior systemic therapy.

Off‑label uses: Outside these approvals, Padcev use is mainly within clinical trials exploring other Nectin‑4–expressing tumors or earlier treatment settings; routine off‑label prescribing in everyday practice is limited, and evidence for non‑urothelial cancers remains investigational and not yet standard of care.

Efficacy expectations: In previously untreated locally advanced or metastatic urothelial cancer, Padcev plus pembrolizumab shrinks tumors in roughly two‑thirds of patients, with about one‑third achieving complete disappearance of visible disease, and approximately doubles both the time before the cancer worsens and median overall survival compared with standard platinum‑based chemotherapy. As single‑agent therapy in previously treated advanced disease, about 40–45% of patients respond and median survival is modestly but meaningfully longer than with conventional chemotherapy. Many patients who respond begin to see improvement on scans after the first few treatment cycles (around 6–9 weeks), but the depth and duration of benefit vary widely between individuals.

Typical dosing and how it is given: Padcev is given as an intravenous (IV) infusion into a vein, usually over about 30 minutes, in an infusion center or clinic. For most adults with locally advanced or metastatic urothelial cancer receiving Padcev plus pembrolizumab, the usual Padcev dose is 1.25 mg/kg (up to a maximum of 125 mg) on Days 1 and 8 of a 21‑day cycle, with pembrolizumab given on Day 1 of each cycle, and treatment continues until the cancer progresses or side effects become unacceptable. As a single‑agent treatment, the standard dose is 1.25 mg/kg (maximum 125 mg) on Days 1, 8, and 15 of a 28‑day cycle, repeated until progression or intolerance.

Perioperative (before and after surgery) muscle‑invasive bladder cancer dosing: In cisplatin‑ineligible adults with muscle‑invasive bladder cancer planned for cystectomy, Padcev is combined with pembrolizumab as neoadjuvant therapy for several 21‑day cycles before surgery and then continued with pembrolizumab as adjuvant therapy after surgery for a defined number of additional cycles; the exact schedule (number of cycles and total duration) is individualized by the oncology team based on the FDA‑approved regimen and the person’s tolerance.

Special dosing instructions and adjustments: Doses are calculated from actual body weight but capped at 125 mg per infusion. No routine dose adjustment is required for mild to severe kidney impairment, but Padcev should generally be avoided in moderate or severe liver impairment. If significant side effects occur (such as troublesome rash, neuropathy, hyperglycemia, or lung inflammation), clinicians may pause treatment, resume at a lower dose level, adjust the schedule, or permanently discontinue therapy according to severity.

What to expect during infusions: Before each cycle, blood tests are usually checked to assess blood counts, kidney and liver function, blood sugar, and electrolytes, and vital signs are monitored during treatment. Additional supportive medicines (for nausea, rash, or other symptoms) may be given as needed. Patients typically go home the same day after observation.

Missed‑dose guidance: If an infusion visit is missed or delayed, the patient should contact the oncology team as soon as possible; the next dose is usually rescheduled and the cycle timing may be adjusted rather than skipped without guidance. Patients should not try to “make up” doses on their own or change the schedule without provider input.

Overdose: Because Padcev is administered in supervised settings from single‑dose vials, accidental overdose is uncommon; if an excessive amount is given, management is supportive—close monitoring for worsened known toxicities (especially skin reactions, neuropathy, hyperglycemia, and organ dysfunction) and appropriate medical treatment.

Common side effects: Very common effects include skin rash or itching, hair loss, fatigue, diarrhea or constipation, nausea, decreased appetite, weight loss, abdominal pain, dry skin or dry eyes, changes in taste, and peripheral neuropathy (numbness, tingling, or burning in hands and feet). Blood tests often show changes in liver and kidney function, increased blood sugar, low blood counts (white cells, red cells, platelets), and shifts in salts such as sodium and phosphate; many of these are mild to moderate but can become serious if not monitored and managed.

Serious or rare adverse effects needing urgent attention: Padcev carries a boxed warning for severe and sometimes fatal skin reactions such as Stevens–Johnson syndrome and toxic epidermal necrolysis, which can start as worsening rash, blistering, peeling skin, painful sores in the mouth or eyes, fever, or flu‑like symptoms. Other serious risks include severe hyperglycemia that can progress to diabetic ketoacidosis, lung inflammation (pneumonitis or interstitial lung disease) causing new or worsening cough or shortness of breath, severe infections (such as pneumonia or urinary tract infection), serious infusion‑site reactions from drug leakage (extravasation), eye disorders (including eye pain, vision changes, or severe dryness), and, more rarely, severe liver problems or multiorgan failure.

Warnings and precautions: Padcev is not established as safe or effective in children and is used in adults only. It can harm an unborn baby, so effective contraception is required during treatment and for a period afterward (at least 2 months for women, 4 months for men, per prescribing information), and it should not be used during pregnancy unless potential benefit clearly outweighs risk; breastfeeding is not recommended during therapy and for 3 weeks after the last dose. Use should be avoided in patients with moderate or severe hepatic impairment, and careful monitoring is needed in those with any liver problems, pre‑existing neuropathy, lung disease, or a history of uncontrolled diabetes or very high blood sugar. No routine dose adjustment is needed for mild to severe renal impairment, but people with kidney disease may still be monitored more closely.

Comparative safety profile: Compared with standard chemotherapy in advanced urothelial cancer, Padcev (alone or with pembrolizumab) provides better cancer control with an overall rate of serious side effects that is similar or somewhat lower, but with a distinct pattern of toxicities—particularly skin reactions, peripheral neuropathy, and hyperglycemia—so dose reductions, treatment delays, or discontinuation for side effects are common.

Side‑effect reporting and safety updates: Patients and caregivers should promptly tell the oncology team about any new or worsening symptoms, especially rash, breathing difficulty, high‑blood‑sugar symptoms, or nerve problems. Side effects can also be reported directly to the U.S. Food and Drug Administration through the MedWatch program (phone or online), and up‑to‑date safety information and boxed warnings are available in the current Padcev prescribing information and on the FDA’s drug safety communications pages.

Drug and supplement interactions: Padcev’s active payload (MMAE) is processed in the body by enzymes and transporters such as CYP3A4 and P‑glycoprotein, so strong dual CYP3A4/P‑gp inhibitors (for example, some antifungals like ketoconazole or itraconazole, certain HIV or hepatitis antivirals, and some macrolide antibiotics) can increase exposure and the risk of side effects; clinicians may avoid these combinations when possible or monitor more closely. There are no major known interactions with most common pain relievers or acid‑reducing medicines, but any new prescription, over‑the‑counter drug, or herbal supplement (including products that affect the liver or blood sugar, such as some weight‑loss or “energy” supplements) should be reviewed with the oncology team.

Food, alcohol, and diagnostic procedures: Padcev infusions are not tied to meals, and no specific food restrictions are required, though maintaining good hydration and nutrition is important. Moderate alcohol intake may further strain the liver or worsen neuropathy in some people and is generally discouraged or limited. Padcev does not have specific known interactions with imaging contrast dyes or most diagnostic procedures, but all treating providers should be informed that the patient is on Padcev.

Conditions and co‑medications requiring caution: Padcev should be used with particular caution—or sometimes avoided—in patients with moderate or severe liver impairment, uncontrolled diabetes or very high baseline blood sugar, significant pre‑existing peripheral neuropathy, active or recent serious lung disease, or active uncontrolled infections. Concomitant use with other drugs that can strongly damage nerves (such as some chemotherapy agents) or cause serious skin reactions may increase toxicity. Use during pregnancy is discouraged because of embryo‑fetal toxicity risk, and breastfeeding is not recommended during treatment and for 3 weeks after the last dose.

Monitoring needs: During Padcev therapy, patients typically have regular blood tests to monitor complete blood counts, kidney and liver function, blood glucose, and electrolytes, along with periodic assessment for neuropathy, skin changes, breathing problems, infections, and eye symptoms; additional tests (such as chest imaging, eye exams, or pancreatic enzymes) may be ordered if specific concerns arise.

Q: What kind of drug is Padcev ejfv, and how is it different from standard chemotherapy?
A: Padcev (enfortumab vedotin‑ejfv) is an antibody‑drug conjugate that delivers a chemotherapy payload directly to cancer cells expressing Nectin‑4, so although it still uses a chemotherapy toxin, it is more targeted than traditional chemotherapy and has a different pattern of side effects.

Q: How soon will I know if Padcev is working?
A: Most people have their first scan after about 2–3 treatment cycles (roughly 6–9 weeks), and many responses are seen at that time, though some patients improve earlier based on symptoms or blood tests and others may need more time.

Q: Will I lose my hair on Padcev?
A: Hair loss or thinning is common with Padcev, especially as treatment continues over multiple cycles, but the degree varies widely; hair usually regrows after treatment stops, although texture or color can change.

Q: Can I receive Padcev if I have kidney problems or diabetes?
A: Padcev can generally be used in people with mild to severe kidney impairment without routine dose changes, but it requires careful monitoring in anyone with significant kidney disease, and those with diabetes or a history of high blood sugar need especially close monitoring and management because Padcev can markedly raise blood sugar.

Q: How long will I stay on Padcev treatment?
A: For advanced or metastatic disease, Padcev (alone or with pembrolizumab) is usually continued as long as it is controlling the cancer and side effects remain manageable, whereas in the perioperative muscle‑invasive bladder cancer setting it is given for a defined number of cycles before and after surgery according to the approved regimen.

Q: Can I work or drive while being treated with Padcev?
A: Many people are able to continue working, driving, and doing daily activities, but fatigue, neuropathy, vision changes, or other side effects can make some tasks unsafe on certain days, so activity decisions should be individualized based on how you feel after each infusion and in consultation with your care team.